arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

NANOVIRICIDES, INC.

NNVC
$1.51 ▼ -0.03 (-1.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
79 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NANOVIRICIDES, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $32.6M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -17.5% ↘
FCF / Share $-0.09 ↗
Trailing P/E —
Price / Book 3.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

79-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-1.79M
↑ +42.9% —
FCF / Share Free cash flow per share
$-0.09
↑ +13.5% —
Long-Term Debt Long-term obligations
$4.73M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
6
Financial Health ↓
0
Cash Quality ↓
60

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 79 quarters